Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting StentMasahiro Natsuaki, Takeshi Kimura, Tetsuya Ishikawa et al.|Journal of the American College of Cardiology|2013Cited by 203
An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized TrialMasahiro Natsuaki, Takeshi Kimura, Hirotoshi Watanabe et al.|Circulation|2023Cited by 145
One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trialMasahiro Natsuaki, Takeshi Kimura, Takeshi Morimoto et al.|Cardiovascular Intervention and Therapeutics|2015Cited by 76
Final 3-Year Outcome of a Randomized Trial Comparing Second-Generation Drug-Eluting Stents Using Either Biodegradable Polymer or Durable PolymerMasahiro Natsuaki, Takeshi Kimura, Ken Kozuma et al.|Circulation Cardiovascular Interventions|2015Cited by 63
Aspirin vs. clopidogrel monotherapy after percutaneous coronary intervention: 1-year follow-up of the STOPDAPT-3 trialHirotoshi Watanabe, Takeshi Kimura, Masahiro Natsuaki et al.|European Heart Journal|2024Cited by 37